Matthews E - Search Results

1

Follow-up testing of rodent carcinogens not positive in the standard genotoxicity testing battery: IWGT workgroup report.

Kasper P, Uno Y, Mauthe R, Asano N, Douglas G, Matthews E, Moore M, Mueller L, Nakajima M, Singer T, Speit G; IWGT Workgroup. Kasper P, et al. Among authors: matthews e. Mutat Res. 2007 Feb 3;627(1):106-16. doi: 10.1016/j.mrgentox.2006.10.007. Epub 2006 Nov 22. Mutat Res. 2007. PMID: 17123861 Review.

2

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints.

Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. Matthews EJ, et al. Regul Toxicol Pharmacol. 2006 Mar;44(2):83-96. doi: 10.1016/j.yrtph.2005.11.003. Epub 2005 Dec 28. Regul Toxicol Pharmacol. 2006. PMID: 16386343

3

Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices.

Contrera JF, Matthews EJ, Daniel Benz R. Contrera JF, et al. Regul Toxicol Pharmacol. 2003 Dec;38(3):243-59. doi: 10.1016/s0273-2300(03)00071-0. Regul Toxicol Pharmacol. 2003. PMID: 14623477

4

Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.

Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. Contrera JF, et al. Regul Toxicol Pharmacol. 2004 Dec;40(3):185-206. doi: 10.1016/j.yrtph.2004.08.004. Regul Toxicol Pharmacol. 2004. PMID: 15546675

5

In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software.

Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. Contrera JF, et al. Regul Toxicol Pharmacol. 2005 Dec;43(3):313-23. doi: 10.1016/j.yrtph.2005.09.001. Epub 2005 Oct 19. Regul Toxicol Pharmacol. 2005. PMID: 16242226

6

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods.

Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. Matthews EJ, et al. Regul Toxicol Pharmacol. 2006 Mar;44(2):97-110. doi: 10.1016/j.yrtph.2005.10.004. Epub 2005 Dec 13. Regul Toxicol Pharmacol. 2006. PMID: 16352383

We constructed 21 modules using the MC4PC program including 13 of 14 (11 genetox and 3 reprotox) tests that we found correlated with results of rodent carcinogenicity bioassays (rcbioassays) [Matthews, E.J., Kruhlak, N.L., Cimino, M.C., Benz, R.D., Contrera, J.F., 2 …

We constructed 21 modules using the MC4PC program including 13 of 14 (11 genetox and 3 reprotox) tests that we found correlated with results …

7

Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.

Matthews EJ, Kruhlak NL, Benz RD, Contrera JF. Matthews EJ, et al. Curr Drug Discov Technol. 2004 Jan;1(1):61-76. doi: 10.2174/1570163043484789. Curr Drug Discov Technol. 2004. PMID: 16472220

8

A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals.

Matthews EJ, Kruhlak NL, Daniel Benz R, Ivanov J, Klopman G, Contrera JF. Matthews EJ, et al. Regul Toxicol Pharmacol. 2007 Mar;47(2):136-55. doi: 10.1016/j.yrtph.2006.10.001. Epub 2006 Dec 18. Regul Toxicol Pharmacol. 2007. PMID: 17175082

9

A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database.

Matthews EJ, Kruhlak NL, Daniel Benz R, Contrera JF. Matthews EJ, et al. Regul Toxicol Pharmacol. 2007 Mar;47(2):115-35. doi: 10.1016/j.yrtph.2006.11.002. Epub 2007 Jan 4. Regul Toxicol Pharmacol. 2007. PMID: 17207562

10

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.

Contrera JF, Kruhlak NL, Matthews EJ, Benz RD. Contrera JF, et al. Regul Toxicol Pharmacol. 2007 Dec;49(3):172-82. doi: 10.1016/j.yrtph.2007.07.001. Epub 2007 Jul 17. Regul Toxicol Pharmacol. 2007. PMID: 17703860

The models were generated using the same weight of evidence scoring method previously developed [Matthews, E.J., Contrera, J.F., 1998. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES s …

The models were generated using the same weight of evidence scoring method previously developed [Matthews, E.J., Contrera, J.F …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

707 results

Search Page